Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-07-01 Sale | 2026-07-02 4:10 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 9,099 | $55.88 | $508,454 | 19,020 (Indirect Direct) | View |
| 2026-06-30 Sale | 2026-07-02 4:08 pm | Royalty Pharma plc | RPRX | Hite Christopher EVP & Chairman, Partnering | 130,000 | $56.5 | $7,345,471 | 499,399 (Indirect Direct) | View |
| 2026-06-24 Sale | 2026-06-25 5:13 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 9,098 | $55.18 | $502,067 | 9,099 (Direct) | View |
| 2026-06-23 Sale | 2026-06-25 5:11 pm | Royalty Pharma plc | RPRX | Hite Christopher EVP & Chairman, Partnering | 150,000 | $54.4 | $8,159,277 | 629,399 (Indirect Direct) | View |
| 2026-05-26 Sale | 2026-05-28 4:48 pm | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 64,399 | $53.98 | $3,476,116 | 50,390 (Indirect Direct) | View |
| 2026-05-20 Sale | 2026-05-21 9:20 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 13,684 | $52.75 | $721,838 | 37,217 (Indirect Direct) | View |
| 2026-05-14 Sale | 2026-05-15 4:38 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 13,684 | $53.06 | $726,137 | 50,901 (Indirect Direct) | View |
| 2026-05-14 Sale | 2026-05-15 4:37 pm | Royalty Pharma plc | RPRX | Norden Gregory Director | 3,045 | $53 | $161,385 | 191,803 (Direct) | View |
| 2026-04-28 Sale | 2026-04-30 5:54 pm | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 34,791 | $49.78 | $1,731,840 | 90,526 (Indirect Direct) | View |
| 2026-04-01 Sale | 2026-04-02 5:58 pm | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 34,791 | $48.33 | $1,681,512 | 83,306 (Indirect Direct) | View |
| 2026-03-23 Sale | 2026-03-25 5:05 pm | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 34,791 | $45.53 | $1,583,989 | 94,276 (Indirect Direct) | View |
| 2026-03-02 Sale | 2026-03-04 5:11 pm | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 34,791 | $46.78 | $1,627,534 | 96,151 (Indirect Direct) | View |
| 2026-02-23 Sale | 2026-02-25 4:08 pm | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 34,791 | $45.32 | $1,576,606 | 98,026 (Indirect Direct) | View |
| 2026-02-02 Sale | 2026-02-04 5:07 pm | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 243,541 | $42.54 | $10,360,814 | 73,275 (Indirect Direct) | View |
| 2026-01-30 Sale | 2026-02-02 4:59 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 20,000 | $41.09 | $821,810 | 26,418 (Indirect Direct) | View |
| 2026-01-23 Sale | 2026-01-26 4:10 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 20,000 | $40.26 | $805,110 | 46,418 (Indirect Direct) | View |
| 2026-01-20 Sale | 2026-01-23 4:48 pm | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 69,582 | $39.35 | $2,737,940 | 86,400 (Indirect Direct) | View |
| 2026-01-16 Sale | 2026-01-20 5:00 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 20,000 | $39.52 | $790,346 | 66,418 (Indirect Direct) | View |
| 2026-01-09 Sale | 2026-01-13 5:37 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 20,000 | $40.78 | $815,634 | 86,418 (Indirect Direct) | View |
| 2026-01-02 Sale | 2026-01-06 4:18 pm | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 69,582 | $38.42 | $2,673,041 | 90,150 (Indirect Direct) | View |
| 2026-01-02 Sale | 2026-01-06 4:17 pm | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 20,000 | $38.48 | $769,650 | 106,418 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-06-30 Option Award | 2026-06-30 5:15 pm | N/A N/A | Royalty Pharma plc | RPRX | Bassler Bonnie L Director | 689 | $54.4 | 79,181 (Direct) | View |
| 2026-06-05 Option Award | 2026-06-08 4:29 pm | N/A N/A | Royalty Pharma plc | RPRX | WEATHERMAN ELIZABETH H Director | 4,545 | $0 | 13,103 (Direct) | View |
| 2026-06-05 Option Award | 2026-06-08 4:28 pm | N/A N/A | Royalty Pharma plc | RPRX | Norden Gregory Director | 4,545 | $0 | 196,348 (Direct) | View |
| 2026-06-05 Option Award | 2026-06-08 4:27 pm | N/A N/A | Royalty Pharma plc | RPRX | LOVE TED W Director | 4,545 | $0 | 58,393 (Direct) | View |
| 2026-06-05 Option Award | 2026-06-08 4:26 pm | N/A N/A | Royalty Pharma plc | RPRX | HODGSON DAVID C Director | 4,545 | $0 | 37,873 (Direct) | View |
| 2026-06-05 Option Award | 2026-06-08 4:24 pm | N/A N/A | Royalty Pharma plc | RPRX | Ho Carole Director | 4,545 | $0 | 13,103 (Direct) | View |
| 2026-06-05 Option Award | 2026-06-08 4:22 pm | N/A N/A | Royalty Pharma plc | RPRX | Engelbert Catherine M. Director | 4,545 | $0 | 55,673 (Direct) | View |
| 2026-06-05 Option Award | 2026-06-08 4:21 pm | N/A N/A | Royalty Pharma plc | RPRX | Coric Vlad Director | 4,545 | $0 | 15,343 (Direct) | View |
| 2026-06-05 Option Award | 2026-06-08 4:20 pm | N/A N/A | Royalty Pharma plc | RPRX | Bassler Bonnie L Director | 4,545 | $0 | 78,492 (Direct) | View |
| 2026-05-06 Option Award | 2026-05-08 5:17 pm | N/A N/A | Royalty Pharma plc | RPRX | Legorreta Pablo G. CEO, Chairman of the Board | 143,821 | $0 | 4,846,979 (Direct) | View |
| 2026-05-06 Option Award | 2026-05-08 5:14 pm | N/A N/A | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 24,263 | $0 | 114,789 (Indirect) | View |
| 2026-05-06 Option Award | 2026-05-08 5:12 pm | N/A N/A | Royalty Pharma plc | RPRX | Hite Christopher EVP & Vice Chairman | 24,263 | $0 | 779,399 (Indirect) | View |
| 2026-05-06 Option Award | 2026-05-08 5:10 pm | N/A N/A | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 18,197 | $0 | 64,585 (Direct) | View |
| 2026-03-31 Option Award | 2026-03-31 4:09 pm | N/A N/A | Royalty Pharma plc | RPRX | Bassler Bonnie L Director | 815 | $45.98 | 73,947 (Direct) | View |
| 2026-02-11 Option Award | 2026-02-13 4:03 pm | N/A N/A | Royalty Pharma plc | RPRX | Legorreta Pablo G. CEO, Chairman of the Board | 157,828 | $0 | 4,703,158 (Direct) | View |
| 2026-02-11 Option Award | 2026-02-13 4:03 pm | N/A N/A | Royalty Pharma plc | RPRX | Coyne Terrance P. EVP & CFO | 26,626 | $0 | 264,481 (Indirect) | View |
| 2026-02-11 Option Award | 2026-02-13 4:02 pm | N/A N/A | Royalty Pharma plc | RPRX | Hite Christopher EVP & Vice Chairman | 26,626 | $0 | 755,136 (Indirect) | View |
| 2026-02-11 Option Award | 2026-02-13 4:02 pm | N/A N/A | Royalty Pharma plc | RPRX | Urist Marshall EVP, Research & Investments | 19,970 | $0 | 46,388 (Direct) | View |
Ownership | 2026-01-06 4:20 pm | N/A N/A | Royalty Pharma plc | RPRX | McGivern Arthur Richard EVP, Investments & GC | 0 | $0 | 730,834 (Indirect) | View |